氨氯地平联合厄贝沙坦治疗原发性高血压的疗效观察

目的观察氨氯地平联合厄贝沙坦治疗原发性高血压的疗效。方法选择来我院治疗的原发性高血压100例为研究对象,随机分为研究组和对照组各50例,研究组予厄贝沙坦（安博维）150 mg/d口服,氨氯地平（络活喜）5 mg/d口服;对照组予厄贝沙坦150 mg/d口服,疗程8周。结果 （1）两组患者的SBP、DBP治疗后均较治疗前明显降低,且治疗后研究组和对照组患者的SBP、DBP组间比较,差异有统计学意义。（2）研究组和对照组患者治疗后的总有效率分别为95.0%、80.0%,差异有统计学意义（χ^2=4.923,P〈0.05）。（3）不良反应：两组患者治疗期间肝肾功能未见明显异常。结论氨氯地平联合厄贝沙坦治疗原发性高血压疗效显著,且安全性好,值得广泛推广和应用。

Efficacy of amlodipine combined irbesartan in treatment of essential hypertension

Objective To investigate the efficacy of irbesartan combined amlodipine in treatment of essential hypertension. Methods A total of 100 cases essential hypertension in our hospital were randomly divided into study group and the control group, 50 cases in each group, the study group were given irbesartan（Upway） 150mg/d orally, amlodipine（Norvasc）5 mg/d orally; control group were given 150 mg/d orally. The total treatment course were 8 weeks. Results（1）The study group and the control group of patients with SBP, DBP after treatment was significantly lower than before treatment, after treatment, SBP and DBP of study group was improved than the control group more significant, the difference was statistically significant.（2）The total efficiency of study group and the control group respectively was 95.0%,and 80.0%, the difference was statistically significant between the two groups（χ^2=4.923, P〈0.05） after treatment.（3）Adverse reactions： During the two groups of patients showed no abnormal kidney function. Conclusion Amlodipine combined with irbesartan in treatment of essential hypertension has significant effect and safety, should be popularized and applied.